ꂃ ꁹ

媒体报道

25

Nov 2024

Fiercebiotech

 

China's HanxBio plans Hong Kong IPO to fund phase 2 solid tumor trial

 
 
23

Apr 2024

 
 

Prnewswire

 

HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)

 
22

Aug 2023

Crownbio

 

Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials

 
22

May 2023

Biospace

 

HanX Biopharmaceuticals announces HX009 IND approval from FDA

 
25

Jul 2022

Prnewswire

 

Anti-PD-1 monoclonal antibody Puyouheng™ (HX-008, Pucotenlimab injection) Co-developed by LEPU BIOPHARMA and HANX BIOPHARMACEUTICALS was approved for marketing in China by NMPA

2

Jan 2025

Biospace

 

Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044